# Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer

> **NCT01624441** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 40 (actual)

## Conditions studied

- Estrogen Receptor Negative
- HER2/Neu Negative
- Male Breast Carcinoma
- Progesterone Receptor Negative
- Recurrent Breast Carcinoma
- Stage IV Breast Cancer AJCC v6 and v7
- Triple-Negative Breast Carcinoma

## Interventions

- **DRUG:** Dinaciclib
- **DRUG:** Epirubicin Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01624441
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-21
- **Primary completion:** 2013-09-10
- **Final completion:** 2013-09-10
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01624441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01624441, "Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01624441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*